AngioDynamics, Inc. (NASDAQ:ANGO) Receives Consensus Recommendation of “Hold” from Analysts

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) have been given a consensus rating of “Hold” by the five analysts that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, two have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $19.50.

ANGO has been the topic of several recent analyst reports. Wall Street Zen upgraded shares of AngioDynamics from a “hold” rating to a “buy” rating in a research report on Saturday. Zacks Research downgraded shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 16th. Canaccord Genuity Group boosted their price target on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. HC Wainwright upped their price target on AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th.

Insider Buying and Selling

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 23,370 shares of the company’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the sale, the senior vice president owned 64,745 shares of the company’s stock, valued at approximately $953,046.40. This represents a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Franklin Resources Inc. raised its position in shares of AngioDynamics by 2.3% in the fourth quarter. Franklin Resources Inc. now owns 48,359 shares of the medical instruments supplier’s stock valued at $621,000 after buying an additional 1,076 shares during the last quarter. Farther Finance Advisors LLC boosted its position in AngioDynamics by 146.4% during the fourth quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 1,199 shares during the last quarter. Deutsche Bank AG grew its stake in AngioDynamics by 5.9% in the 4th quarter. Deutsche Bank AG now owns 35,584 shares of the medical instruments supplier’s stock worth $457,000 after acquiring an additional 1,992 shares during the period. Kemnay Advisory Services Inc. purchased a new stake in AngioDynamics in the 4th quarter worth approximately $27,000. Finally, Price T Rowe Associates Inc. MD raised its holdings in AngioDynamics by 5.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 44,298 shares of the medical instruments supplier’s stock valued at $569,000 after acquiring an additional 2,263 shares during the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Stock Performance

Shares of NASDAQ ANGO opened at $15.95 on Wednesday. The firm has a market capitalization of $659.21 million, a P/E ratio of -18.33 and a beta of 0.33. AngioDynamics has a one year low of $9.39 and a one year high of $16.29. The company’s fifty day moving average is $14.11 and its two-hundred day moving average is $12.14.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. The business had revenue of $86.61 million for the quarter, compared to analysts’ expectations of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, sell-side analysts forecast that AngioDynamics will post -0.25 earnings per share for the current fiscal year.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.